Dr. Finn on New CDK 4/6 Inhibitors for Breast Cancer

Richard S. Finn, MD
Published Online: Monday, August 19, 2013
Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.

Other CDK inhibitors have been around a lot longer than palbociclib but have not broken out of the pack to show robust activity. Palbociclib, as a first-in-class CDK 4/6 inhibitor, has shown such benefit that there are now other CDK 4/6 inhibitors being developed.

These other drugs are in early phase and a ways behind, Finn says, so it remains to be seen how they can compete with palbociclib in the space.

Online CME Activities
Free CME from PER
Immunotherapeutic Approaches to the Treatment of Squamous Non-Small Cell Lung Cancer
Clinical Vignettes in Multiple Myeloma
Clinical Vignette Series: Mitigating and Managing Adverse Events in Hematology
Angiogenesis Inhibitors for Gastrointestinal Cancers: Update From the 2015 Gastrointestinal Cancers Symposium
More Reading
$auto_registration$